Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations

Gynecologic Oncology

Volumn 76, Issue 1, 2000, Pages 45-50

  Zweemer, Ronald P ^a,b   Van Diest, Paul J ^a   Verheijen, René H M ^a   Ryan, Andy ^b   Gille, Johan J P ^a   Sijmons, Rolf H ^c   Jacobs, Ian J ^b   Menko, Fred H ^a   Kenemans, Peter ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RISK; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; ONCOGENE; OVARIECTOMY; PRIORITY JOURNAL; PROPHYLAXIS; UTERINE TUBE CARCINOMA;

EID: 0033976892     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5623     Document Type: Article

References (18)

1. Narod S A, Madlensky L, Bradley L. Hereditary and familial ovarian cancer in southern Ontario. Cancer. 74:1994;2341-2346.
2. Ford D, Easton D F, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 62:1998;676-689.
3. Easton D F, Ford D, Bishop D T. Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet. 56:1995;265-271.
4. Ford D, Easton D F, Bishop D T, Narod S A, Goldgar D E. Risks of cancer in BRCA1 mutation carriers. Lancet. 343:1994;692-695.
5. Tonin P, Moslehi R, Green R. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. Hum Genet. 95:1995;545-550.
6. Schubert E L, Lee M K, Mefford H C. BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet. 60:1997;1031-1040.
7. Visser, O, Coebergh, J, WW, Otter, R, (eds), Gynaecological Tumors in the Netherlands 1989-1993, Utrecht, The Netherlands Cancer Registry, Association of Comprehensive Cancer Centres, 1997.
8. Zweemer R P, Verheijen R HM, Gille J JP, van Diest P J, Pals G, Menko F H. Clinical and genetic evaluation of 30 ovarian cancer families. Am J Obstet Gynecol. 178:1998;85-90.
9. Petrij-Bosch A, Peelen T, van Vliet M. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet. 17:1997;341-345.
10. Hu C Y, Taymor M L, Hertig A T. Primary carcinoma of the Fallopian tube. Am J Obstet Gynecol. 59:1950;58.
11. Sedlis A. Primary carcinoma of the Fallopian tube. Obstet Gynecol Surv. 16:1961;209-226.
12. Yoonessi M. Carcinoma of the Fallopian tube. Obstet Gynecol Surv. 34:1979;257.
13. Rose P G, Piver M S, Tskuda Y. Fallopian tube cancer: The Roswell Park experience. Cancer. 66:1990;2661-2667.
14. Smith S A, Easton D F, Evans D G, Ponder B A. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet. 2:1992;128-131.
15. Woolas R, Jacobs I, Prys Davies A, Leake J, Brown C, Grudzinskas J. What is the true incidence of Fallopian tube carcinoma. Int J Gynaecol Cancer. 4:1996;348.
16. Tobacman J K, Greene M H, Tucker M A, Costa J, Kase R, Fraumeni J F Jr. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet. 2:1982;795-797.
17. Piver M S, Jishi M F, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer. 71:1993;2751-2755.
18. Struewing J P, Watson P, Easton D F, Ponder B AJ, Lynch H T, Tucker M A. Prophylactic oophorectomy in inherited breast/ovarian cancer families. Natl Cancer Inst. 17:1995;33-35.